Ryan Watts, CEO and Co-Founder of Denali Therapeutics

Company Overview

• Denali Therapeutics was founded in May 2015 (nearly 7 years prior to the interview) by CEO Dr. Ryan Watts to address the unmet need in neurodegenerative diseases.
• The company's core mission is to defeat degenerative diseases like Alzheimer's, Parkinson's, and ALS by targeting genetic underpinnings and crossing the blood-brain barrier (BBB).
• Denali currently maintains a pipeline of 15 programs, 6 of which are clinical-stage.
• The company has transitioned from 11 years of work at Genentech (yielding 2 clinical-stage programs) to 7 years at Denali (yielding 10 molecules tested and 3 discontinued).

Strategic Pillars for Success

• Genetic Architecture: The founding was preceded by an explosion in genetic insight (2008–2015) linking specific genes to Alzheimer's, Parkinson's, and ALS, providing clear biological targets.
• Brain Delivery Technology: Denali invented proprietary methods to hitchhike large biotherapeutics across the BBB using natural transporters (e.g., for iron or glucose), a unique capability within the biopharma space.
• Biomarkers: Heavy investment in genetic, fluid-based, and imaging biomarkers allows for early disease tracking and real-time verification that medicines are affecting the intended targets.
• Pipeline Diversification: To sustain investor confidence and team morale while targeting the "20-year" goal of curing Alzheimer's, Denali focuses on shorter-term milestones in lysosomal storage diseases where success rates are higher (90%).

Clinical Progress & Timeline

• The company is initiating pivotal late-stage studies for Parkinson's disease targeting a specific genetic variant.
• A late-stage study for Hunter syndrome (a lysosomal storage disease) has begun, aiming for approval of an enzyme therapy that crosses the BBB.
• A Phase 2 efficacy study for ALS was announced shortly before the interview.
• Denali has active programs addressing cancer metastasis to the brain (specifically breast cancer) and potential psychiatric disorders like depression.

Personal Motivation & Family History

• Dr. Watts' mother was diagnosed with Alzheimer's approximately 8–9 years into his tenure at Genentech; she passed away in late 2020.
• The diagnosis was identified by repeated storytelling and memory loss over an 11-year period; she never visited the Denali office due to inability to travel.
• Dr. Watts and his wife were tested for genetic risk and found to carry the APOE4 gene, which confers a 3-fold increased risk for one copy and a 14-fold risk for two copies; 25% of the general population carries at least one copy.
• The emotional climax of the interview notes that the first word Dr. Watts used to describe his mother's death was "relief," citing the cessation of her suffering rather than a lack of love.
• Dr. Watts shared a specific genetic discovery: a mutation in the APP gene found in individuals aged 80–90 without Alzheimer's reduces amyloid production by 40%, offering strong evidence for preventative strategies.

Industry Trends & Future Outlook

• Shift to Prevention: The field is moving from treating late-stage dementia (where 99.7% of drug failures occur) to preventative care targeting disease onset in the 40s or 50s.
• Success Rate Variance: While general drug success rates are low (93% failure in cancer), success rates in lysosomal storage diseases reach 90%, validating the "technology-first" approach.
• Regulatory Challenges: Approving medicines for prevention requires redefining endpoints, as patients may not yet exhibit clinical dementia symptoms.
• Future Vision: Dr. Watts predicts that within 10–15 years, preventative measures involving brain scans and early protein removal will become standard for high-risk populations.

Leadership & Organizational Philosophy

• Denali selects for employees who embrace failure as a necessary step toward discovery, citing the company's "20-year" horizon.
• The company utilizes "Denali Connections," a video initiative documenting personal stories of team members to foster purpose and empathy.
• Dr. Watts advises aspiring biotech entrepreneurs to align their work with a deep sense of personal purpose to sustain motivation through high-difficulty challenges.
• A notable internal milestone occurred when clinical data confirming the BBB technology's success in humans was received while Dr. Watts was filming a family video; he immediately contacted his mother, who was then too cognitively impaired to understand the significance.